Current Trials
ACTIVELY ENROLLING CLINICAL STUDIES AT THE CRCNJ
To find out if you’re eligible, contact us at 973 850 4622 or click on the link to the trial of interest, complete the online form, and we will contact you.
Open
Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
SPONSOR: vTv Therapeutics
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 9 months (in Part 1) or 21 months (in Part 2). clinicaltrials.gov.
Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease (GAIN Trial)
SPONSOR: Cortexyme Inc.
This is a randomized, double-blind, placebo-controlled study that will assess the efficacy, safety, and tolerability of 2 dose levels of COR388 in subjects with a clinical diagnosis of mild to moderate AD dementia. clinicaltrials.gov.
Multi-Center Study of Sensory Stimulation to Improve Brain Function (Overture)
SPONSOR: Cognito
The Overture Study is a randomized, controlled, single-blind multi-center clinical trial using the GammaSense Stimulation system to study safety, tolerability, and efficacy in people with mild to moderate cognitive impairment. clinicaltrials.gov
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer’s Disease (AD)
SPONSOR: Roche
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 104. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose. clinicaltrials.gov.
A Study of LY3154207 in Participants With Parkinson's Disease Dementia (PRESENCE)
SPONSOR: Eli Lilly
A randomized placebo-controlled trial in individuals with Parkinson's disease dementia to evaluate the safety and efficacy of three doses of study drug LY3154207 in participants with mild-to-moderate Parkinson's disease dementia treated for 12 weeks. clinicaltrials.gov.
Active but closed to enrollment
Phase 2 Study of BIIB092 in Participants With Early Alzheimer’s Disease (TANGO)
SPONSOR: BIOGEN
To evaluate the safety and tolerability of BIIB092 in participants with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease (AD) or with mild AD. To evaluate the efficacy of multiple doses of BIIB092 in slowing cognitive and functional impairment in participants with MCI due to AD or with mild AD. To evaluate the immunogenicity of BIIB092 after multiple doses in participants with MCI due to AD or with mild AD. clinicaltrials.gov.
CLOSED TO ENROLLMENT
A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer’s Disease (MissionAD1)
SPONSOR: EISAI CO., LTD.
The name of this trial is MissionAD1. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer’s Disease (EAD) including Mild Cognitive Impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety of elenbecestat. clinicaltrials.gov.
CLOSED TO ENROLLMENT
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer’s Disease
SPONSOR: Eli Lilly
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD). clinicaltrials.gov.
CLOSED TO ENROLLMENT
A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease (Neurotrope)
SPONSOR: Neurotrope
This is a randomized double-blind placebo-controlled study comparing different doses of bryostatin for the treatment of moderately severe to severe Alzheimer's disease. The study is 15 weeks in duration, including a safety and efficacy evaluation 30 days after the last dose of study drug. clinicaltrials.gov
CLOSED TO ENROLLMENT
“CREAD Study” A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer’s Disease (AD)”
SPONSOR: HOFFMANN-LA ROCHE.
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The final efficacy and safety assessment will be performed 52 weeks after the last crenezumab dose.
CLOSED TO ENROLLMENT
Click here to make an appointment or call 973-850-4622 to learn more about how The CRCNJ can help.
